Tislelizumab
beigene,novartis
we re excited to present new data from our rationale 306 trial at s world congress on gi #cancer, building on the interim results presented at #asco22. 
Formerly @BeiGeneUSA, we're transforming the biotech industry, creating impactful medicines for patients globally. Community guidelines: https://t.co/bZCHuaXk0s